硼替佐米联合来那度胺治疗多发性骨髓瘤的效果及对血清炎性因子的影响
Effect of Bortezomib Therapy Combined with Lenalidomide in Multiple Myeloma and Its Effect on Serum Inflammatory Factors
杨丽 1翟立富1
作者信息
- 1. 新泰市人民医院血液内科,山东 新泰 271200
- 折叠
摘要
目的 分析硼替佐米联合来那度胺治疗多发性骨髓瘤的效果.方法 目的选取新泰市人民医院2019年8月—2023年12月共80例多发性骨髓瘤患者,以硼替佐米+地塞米松治疗的40例患者作为对照组;以硼替佐米+地塞米松+来那度胺治疗的40例患者作为研究组,分别于治疗前后对比两组患者生化指标、免疫指标、炎性因子、不良反应.结果 治疗后,研究组β2-微球蛋白水平为(3.89±0.19)µg/mL,单克隆蛋白水平为(23.64±3.15)g/L,骨髓瘤细胞比例为(13.92±2.68)%,优于对照组的(6.25±0.25)µg/mL、(28.93±3.23)g/L、(17.38±2.59)%,差异有统计学意义(t=14.426、7.241、5.908,P均<0.05);治疗后,研究组免疫指标较对照组优,差异有统计学意义(P均<0.05);两组不良事件对比,差异无统计学意义(P>0.05);治疗后,研究组炎性因子水平较对照组低,差异有统计学意义(P均<0.05).结论 硼替佐米治疗联合来那度胺治疗多发性骨髓瘤,能够改善生化指标水平,提高患者免疫功能,降低炎性反应,且不增加不良反应.
Abstract
Objective To analyze the effect of bortezomib therapy combined with lenalidomide in the treatment of mul-tiple myeloma.Methods A total of eighty patients with multiple myeloma in People's Hospital of Xintai from August 2019 to December 2023 were objectively selected,and forty patients treated with bortezomib+dexamethasone were selected as the control group;and forty patients treated with bortezomib+dexamethasone+lenalidomide were se-lected as the study group.Two groups of biochemical indexes,immune indexes,inflammatory factors and adverse reac-tions were compared before and after treatment.Results After treatment,the study group β-2-microglobulin level was(3.89±0.19)µg/mL,the monoclonal protein level was(23.64±3.15)g/L,the proportion of myeloma cells was(13.92±2.68)%,better than(6.25±0.25)µg/mL,(28.93±3.23)g/L,(17.38±2.59)%in the control group,the differences were statistically significant(t=14.426,7.241,4.5.908,all P<0.05).After treatment,the immune indexes in the study group were lower than those in the control group,the differences were statistically significant(all P<0.05).There was no sta-tistically significant difference in adverse events between two groups(P>0.05).After treatment,the level of inflamma-tory factors in the study group were lower than those in the the control group,the differences were statistically signifi-cant(all P<0.05).Conclusion Bortezomib therapy combined with lenalidomide for multiple myeloma can improve bio-chemical parameters,improve patient immune function,and reduce inflammatory response without increasing adverse effects.
关键词
硼替佐米/来那度胺/多发性骨髓瘤/生化指标/免疫功能/炎性反应Key words
Bortezomib/Lenalidomide/Multiple myeloma/Biochemical index/Immune function/Inflammatory response引用本文复制引用
出版年
2024
NETL
NSTL
万方数据